

## **ASX Release**

### 12 December 2024

# Cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Acrux Ltd (ASX:ACR) (Company) gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act).

The Company refers to its announcement on 12 December 2024 whereby 1,860,156 fully paid ordinary shares (**Shares**) have been issued to Non-executive Directors following the exercise of vested rights.

The Company gives notice that:

- the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (2) this notice is being given under section 708A(5)(e) of the Act;
- (3) as at the date of this notice, it has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
    (b) section 674 of the Act; and
- (4) as at the date of this notice, there is no information that is "excluded information" (as defined in sections 708A(7) and (8) of the Act) which is required to be set out in this notice under section 708A(6)(e) of the Act.

#### This announcement has been authorised for release to the ASX by the Board of Directors.

#### For more information, please contact:

Michael Kotsanis CEO & Managing Director

E: michael.kotsanis@acrux.com.au

Joanna Johnson CFO & Company Secretary E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

#### About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au